Du är här

2014-04-30

Novavax, Inc.: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

University of Maryland School of Medicine Study Published in Vaccine
Highlights First Potential Effective Means for Preventing MERS Coronavirus
Outbreak

BALTIMORE and GAITHERSBURG, Md., April 30, 2014 (GLOBE NEWSWIRE) -- The
University of Maryland School of Medicine (UM SOM) and Novavax, Inc.
(Nasdaq:NVAX) today announced that an investigational vaccine candidate
developed by Novavax against the recently emerged Middle East Respiratory
Syndrome Coronavirus (MERS-CoV) blocked infection in laboratory studies. UM
SOM and Novavax also reported that a vaccine candidate against Severe Acute
Respiratory Syndrome Coronavirus (SARS-CoV) developed by Novavax on a similar
platform also inhibited virus infection. Researchers reported these findings
in an article published in the April 13, 2014 issue ofVaccine
1.

Historically, vaccine strategies for emerging pathogens have been limited due
to the sudden nature in which the virus first appears and delayed by the
protracted traditional vaccine development process. This peer-reviewed
manuscript describes a novel method to rapidly develop vaccines against
previously unknown viruses, such as MERS-CoV, which appear suddenly and cause
severe illnesses in humans. The experimental vaccines, which were tested in
conjunction with Novavax' proprietary adjuvant Matrix-M(TM), induced
neutralizing antibodies, or immune responses, that prevent viruses from
infecting cells.

"Our protein nanoparticle vaccine technology is proving to have the potential
to respond rapidly to emerging viruses such as MERS-CoV and certain potential
pandemic influenza strains, addressing what are clearly urgent public health
needs," saidGale Smith, Ph.D., Vice President of Vaccine Development at
Novavax. "Novavax will continue to evaluate this technology to produce highly
immunogenic nanoparticles for coronavirus, influenza, and other human disease
pathogens with the potential for pandemic and sustained human to human
transmission."

"The emergence of SARS-CoV and MERS-CoV demonstrates how coronaviruses can
spillover from animals into humans at any time, causing lethal disease,"
saidMatthew B. Frieman, Ph.D., Assistant Professor of Microbiology and
Immunology at the University of Maryland School of Medicine and corresponding
author on the publication. "Despite efforts to create a vaccine against
SARS-CoV, no vaccine candidate has, to date, been successfully licensed for
use. We have demonstrated that this novel method rapidly creates SARS-CoV and
MERS-CoV vaccines that induce neutralizing antibodies in mice."

"The University of Maryland School of Medicine investigators are continually
working toward a better understanding of the interactions between the human
immune system and a variety of known and novel harmful microbes," said E.
Albert Reece, Vice President of Medical Affairs, the University of Maryland
and the John Z. and Akiko Bowers Distinguished Professor and Dean, University
of Maryland School of Medicine. "This makes our faculty poised to respond to
emerging infectious diseases, such as MERS-CoV, which threaten the health and
wellbeing of the global population."

The vaccine candidates were made using Novavax' recombinant nanoparticle
vaccine technology and based on the major surface spike (S) protein, a
SARS-CoV and MERS-CoV surface protein responsible for attaching the virus to
cells. Novavax previously demonstrated that spike protein nanoparticles could
protect animals against lethal live challenge using the SARS-CoV virus2.

About MERS-CoV

MERS-CoV, first identified in 2012, is one of a family of viruses with the
potential to rapidly spread from a benign infection of animals to cause
severe disease in humans. In 2003, a previously unknown coronavirus called
SARS-CoV caused an outbreak that raised health alarms by infecting over 8,000
individuals and killing 775. According to the World Health Organization, the
novel MERS-CoV thus far has resulted in 107 deaths out of 345 infections, the
majority of which are characterized by severe illness and hospitalizations.
Both diseases were marked by a jump from animals to people and while SARS-CoV
spread more quickly in humans, MERS-CoV is proving to be more deadly.

About University of Maryland School of Medicine

Established in 1807, the University of Maryland School of Medicine was the
first public medical school in the United States, and the first to institute
a residency-training program. The School of Medicine was the founding school
of the University of Maryland and today is an integral part of the 11-campus
University System of Maryland. On the University of Maryland's Baltimore
campus, the School of Medicine serves as the anchor for a large academic
health center which aims to provide the best medical education, conduct the
most innovative biomedical research and provide the best patient care and
community service to Maryland and beyond.www.medschool.umaryland.edu.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant
protein nanoparticle vaccine technology, the company produces vaccine
candidates to efficiently and effectively respond to both known and newly
emergent diseases. Novavax is involved in several international partnerships,
including collaborations with Cadila Pharmaceuticals of India, LG Life
Sciences of Korea, PATH and recently acquired Isconova AB, a leading vaccine
adjuvant company located in Sweden. Together, Novavax' network supports its
global commercialization strategy to create real and lasting change in the
biopharmaceutical and vaccinology fields. Additional information about
Novavax is available on the company's website,novavax.com.

About Vaccine

Vaccine
is the pre-eminent journal for those interested in vaccines and vaccination.
It is the official journal of The Edward Jenner Society, The International
Society for Vaccines and The Japanese Society for Vaccinology.
www.elsevier.com/locate/vaccine

References:

1. C. M. Colemanet al
. Purified coronavirus Spike protein nanoparticles induce coronavirus
neutralizing antibodies in mice.Vaccine
. In press, April 13, 2014.
2. Y. Liuet al
. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV, 2011; 29(38): 6606-6613.Copies of the paper are available to credentialed journalists upon request;
please contact Elsevier's Newsroom at newsroom@elsevier.com or
+31-20-4853564.

Novavax Inc., Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing
development of its vaccine and adjuvant products are forward-looking
statements. Novavax cautions that these forward looking statements are
subject to numerous risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied by such statements.
These risks and uncertainties include those identified under the heading
"Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended
December 31, 2013, filed with the Securities and Exchange Commission (SEC).
We caution investors not to place considerable reliance on the
forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available at sec.gov, for a
discussion of these and other risks and uncertainties. The forward-looking
statements in this press release speak only as of the date of this document,
and we undertake no obligation to update or revise any of the statements. Our
business is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.

CONTACT: Media Contacts:
Christopher Hardwick
(chardwick@som.umaryland.edu)
University of Maryland School of Medicine
410-706-5260

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
David Schull or Andrea Flynn, Ph.D.
david.schull@russopartnersllc.com
andrea.flynn@russopartnersllc.com
Russo Partners
212-845-4271

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#1781322

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.